https://krishi.icar.gov.in/jspui/bitstream/123456789/28481/1/Nanotherapy_BIOPHA_2017.pdf

Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world

Efficient delivery of drugs to living cells is still a major challenge. Currently, most methods rely on the endocytotic pathway resulting in low delivery efficiency due to limited endosomal escape and/or degradation in lysosomes. Here, we report a new method for direct drug delivery into the cytosol of live cells in vitro and in vivo utilizing targeted membrane fusion between liposomes and live cells. A pair of complementary coiled-coil lipopeptides was embedded in the lipid bilayer of liposomes and cell membranes respectively, resulting in targeted membrane fusion with concomitant release of liposome encapsulated cargo including fluorescent dyes and the cytotoxic drug doxorubicin. Using a wide spectrum of endocytosis inhibitors and endosome trackers, we demonstrate that the major site of cargo release is at the plasma membrane. This method thus allows for the quick and efficient delivery of drugs and is expected to have many in vitro, ex vivo, and in vivo applications.

/pdf/drug-delivery-via-cell-membrane-fusion-using-lipopeptide-27eq6zutli.pdf

Drug Delivery via Cell Membrane Fusion Using Lipopeptide Modified Liposomes.

Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance.

Nucleic acids are a promising type of therapeutic for the treatment of a wide range of conditions, including cancer, but they also pose many delivery challenges. For efficient and safe delivery to cancer cells, nucleic acids must generally be packaged into a vehicle, such as a nanoparticle, that will allow them to be taken up by the target cells and then released in the appropriate cellular compartment to function. As with other types of therapeutics, delivery vehicles for nucleic acids must also be designed to avoid unwanted side effects; thus, the ability of such carriers to target their cargo to cancer cells is crucial. This review will discuss classes of nucleic acids, hurdles that must be overcome for effective intracellular delivery, types of non-viral nanomaterials used as delivery vehicles, and the different strategies that can be employed to target nucleic acid delivery specifically to tumor cells. Moreover, nanoparticle designs that facilitate multiplexed delivery of combinations of nucleic acids will be reviewed.

Cancer-Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery

Carbon nanotube scaffolds as emerging nanoplatform for myocardial tissue regeneration: A review of recent developments and therapeutic implications.

A key barrier to the development of gene therapy remains the lack of safe, efficient and easily controllable vehicles for gene delivery. The fundamental problems associated with the viral vehicles, e.g. lack of specificity and immunogenic potential, have driven the development of non-viral systems of gene delivery. In the last decade, studies on p53 gene replacement therapy have dominated the literature. Although clinical trials of p53 gene therapy have achieved limited success, it remains the only tumor suppressor gene to be evaluated formally in clinical trials for cancer treatment, with increasing focus on delivery using non-viral systems. In this article, we particularly review current investigations on p53 gene delivery using non-viral methods, including both physical and chemical approaches, with an emphasis on the latter. The existing opportunities and challenges for successful p53 cancer gene therapy are also discussed.

Fuming Qiu

Papers

Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy.